ABCG2 and acute myeloid leukemia: ABCG2-mediated efflux block was also demonstrated by venetoclax, bcl-2 inhibitors originally approved for lymphoproliferative diseases and recently employed in elderly acute myeloid leukemia in association with hypomethylating agents [120].